Mechanisms of Antibiotic Resistance

Correct Answer

B — Enzymatic drug inactivation — hydrolysis of the beta-lactam ring, destroying antibiotic activity before the drug reaches its target

Rationale

Beta-lactamases are classified as enzymatic drug inactivation mechanisms — one of the four major categories of antibiotic resistance alongside target modification, drug efflux, and target bypass. Beta-lactamases hydrolyze the beta-lactam ring, rendering the drug incapable of binding penicillin-binding proteins. Target modification (option A) describes the mechanism of MRSA penicillin-binding protein 2a. Drug efflux (option C) describes pump-mediated resistance. Target bypass (option D) also describes PBP2a. Knowing that beta-lactamases represent the enzymatic inactivation class of resistance mechanism is the task here.

Correct Answer

D — A fixed, species-level property present in every member of the species regardless of prior antibiotic exposure; it is predictable, stable, and requires no selective pressure to be expressed

Rationale

Intrinsic resistance is an inherent, species-level characteristic that exists independently of any antibiotic exposure or selective pressure. Every member of the species carries the same structural or physiological property that renders a particular antibiotic class ineffective — for example, all gram-negative bacteria are intrinsically resistant to vancomycin because the drug cannot penetrate the outer membrane; all Enterococcus faecalis are intrinsically resistant to all cephalosporins regardless of the cephalosporin generation; and Pseudomonas aeruginosa is intrinsically resistant to many penicillins due to constitutive efflux pump expression combined with limited outer membrane permeability. Because intrinsic resistance is predictable and uniform within a species, susceptibility testing is not needed for drug-organism combinations known to exhibit it. Acquired resistance, by contrast, arises through mutation or horizontal gene transfer in organisms that were previously susceptible, requires selective or stochastic events to emerge, and is not present in all members of the species.

Correct Answer

A — Serine enzymes evolved from narrow-spectrum beta-lactamases through point mutations that extend hydrolytic activity to third-generation cephalosporins and aztreonam while sparing carbapenems

Rationale

Extended-spectrum beta-lactamases are classified as serine-based enzymes that evolved from narrow-spectrum predecessors through mutational expansion of their substrate range. The defining class characteristics are serine catalytic mechanism and carbapenem-sparing substrate boundary — they do not hydrolyze carbapenems, which is what makes them clinically distinct from carbapenemases. Option B describes metallo-beta-lactamases. Option C describes AmpC cephalosporinases. Option D describes KPC-type serine carbapenemases. Knowing the ESBL's classification as a serine enzyme with extended but carbapenem-sparing spectrum is the task here.

Correct Answer

C — Enzymatic drug inactivation — they chemically modify the aminoglycoside molecule, reducing its ability to bind the ribosomal target

Rationale

Aminoglycoside-modifying enzymes are classified as enzymatic drug inactivation mechanisms — the same major resistance category as beta-lactamases, though their chemical reaction is modification rather than hydrolysis. They alter the aminoglycoside molecule itself, reducing its ribosomal binding affinity. Ribosomal methylation (option A) is a separate resistance mechanism also conferring aminoglycoside resistance but through target modification rather than drug modification. Efflux and target bypass are distinct categories. Knowing that aminoglycoside-modifying enzymes belong to the enzymatic drug inactivation resistance class is the task here.

Correct Answer

B — Target bypass — PBP2a is an alternative transpeptidase with low beta-lactam affinity that continues cell wall synthesis when all native penicillin-binding proteins are inhibited

Rationale

The mecA gene product, penicillin-binding protein 2a, exemplifies the target bypass class of resistance — the organism acquires an alternative enzyme that performs the essential function while evading the drug. PBP2a is not a beta-lactamase (it does not hydrolyze the drug), not an efflux pump, and does not modify existing penicillin-binding proteins. Knowing that mecA-mediated MRSA resistance is classified as target bypass is the task here.

Correct Answer

A — Reduced drug accumulation — active transport proteins that extrude antibiotics from the bacterial cell before they reach inhibitory intracellular concentrations

Rationale

Bacterial efflux pumps are classified as reduced drug accumulation mechanisms — distinct from enzymatic inactivation, target modification, and target bypass. By actively transporting antibiotics out of the cell, efflux pumps prevent drug concentrations at the target from reaching inhibitory levels. This classification as a reduced accumulation mechanism is the key categorical label. Knowing that efflux pumps represent the reduced drug accumulation resistance class, distinct from the other major resistance categories, is the task here.

Correct Answer

C — Intrinsic resistance is a stable species-level property present before any antibiotic exposure; acquired resistance arises through mutation or horizontal gene transfer in previously susceptible organisms; antibiotics select for pre-existing resistant variants rather than causing mutations

Rationale

Intrinsic resistance is the natural, fixed insensitivity of a species to a drug class — present in all members before any antibiotic contact, arising from the organism's own structural or metabolic properties. Classic examples are gram-negative outer membrane exclusion of vancomycin and enterococcal intrinsic resistance to cephalosporins. Acquired resistance, by contrast, arises in previously susceptible individual organisms through random spontaneous chromosomal mutations or through acquisition of resistance determinants from other bacteria via horizontal gene transfer mechanisms including conjugation, transformation, and transduction. The relationship between antibiotics and resistance is mechanistically important: antibiotics do not cause mutations. Resistant mutants arise spontaneously in any bacterial population at low frequency. Antibiotic exposure kills susceptible organisms while allowing pre-existing resistant variants to survive and replicate — selection, not induction. Subtherapeutic concentrations are especially prone to this selection because they kill susceptible bacteria while permitting partially resistant mutants to survive.

Correct Answer

A — ESBL-producing organisms may test susceptible to ceftriaxone or ceftazidime at standard inoculum but fail clinically in serious infections such as bacteremia; carbapenems are the treatment of choice for serious infections caused by ESBL-producing organisms regardless of reported cephalosporin susceptibility

Rationale

The inoculum effect is central to understanding this pitfall. At the standard inoculum used for disk diffusion or broth microdilution susceptibility testing, enough beta-lactam antibiotic may overwhelm the beta-lactamase enzyme present, producing a susceptible result. At the much higher bacterial densities found in clinical infections — particularly bacteremia — the aggregate beta-lactamase activity overwhelms the antibiotic, hydrolysis outpaces drug concentration, and treatment fails despite in vitro susceptibility. This phenomenon — treatment failure with a drug the laboratory called susceptible — is well-documented in ESBL-producing Klebsiella and Escherichia coli bacteremia treated with extended-spectrum cephalosporins. Carbapenems are not hydrolyzed by extended-spectrum beta-lactamases and remain the recommended definitive therapy for serious ESBL-producing infections. Piperacillin-tazobactam has shown inconsistent efficacy in ESBL bacteremia clinical trials and guidelines recommend against relying on it for serious ESBL infections.

Correct Answer

D — KPC is a serine carbapenemase inhibited by avibactam; NDM is a metallo-beta-lactamase that uses a zinc-dependent catalytic mechanism not targeted by avibactam, making ceftazidime-avibactam ineffective against NDM producers

Rationale

Avibactam is a non-beta-lactam beta-lactamase inhibitor that covalently binds and inhibits serine-based enzymes, including KPC and OXA-48 carbapenemases. NDM is a metallo-beta-lactamase — its catalytic mechanism uses zinc ions rather than an active-site serine, and avibactam has no activity against zinc-dependent enzymes. Because ceftazidime-avibactam relies on avibactam to protect ceftazidime from beta-lactamase hydrolysis, it fails when NDM is the resistance mechanism. Aztreonam-avibactam is the preferred agent for NDM producers: aztreonam is not hydrolyzed by metallo-beta-lactamases, and avibactam protects against any co-produced serine enzymes. Understanding the serine vs. metallo-beta-lactamase classification distinction is essential to predicting inhibitor susceptibility.

Correct Answer

B — Organisms such as Enterobacter, Serratia, and Pseudomonas carry chromosomal AmpC genes that are normally expressed at low levels; third-generation cephalosporins can select for mutants that constitutively overproduce the enzyme, causing treatment failure even when the initial isolate tested susceptible

Rationale

Certain gram-negative organisms — including Enterobacter cloacae, Serratia marcescens, Citrobacter freundii, Morganella morganii, Providencia species, and Pseudomonas aeruginosa — carry chromosomal AmpC beta-lactamase genes that are normally kept at low expression levels. Third-generation cephalosporins such as ceftriaxone and cefotaxime are potent inducers of AmpC transcription in these organisms. More clinically consequential, the large bacterial populations present in serious infections contain rare mutants with defects in the AmpC regulatory system, causing constitutive high-level AmpC overproduction. Third-generation cephalosporins selectively kill susceptible organisms while allowing these constitutive overproducer mutants to expand — a phenomenon called derepression. The initial susceptibility test, performed on the baseline isolate before therapy, does not detect this pre-existing mutant subpopulation. Clinical failures during therapy with initially susceptible isolates from these species are well-documented. Fourth-generation cephalosporins (cefepime) and carbapenems are more stable to AmpC hydrolysis and are preferred for serious infections caused by AmpC-harboring organisms.

Correct Answer

A — Conjugation (direct cell-to-cell plasmid transfer via a pilus), transformation (uptake of free deoxyribonucleic acid from lysed bacteria), and transduction (bacteriophage-mediated deoxyribonucleic acid transfer); conjugation is most clinically important because plasmids can carry multiple resistance genes, enabling co-transfer of resistance to several antibiotic classes in a single event

Rationale

Horizontal gene transfer enables bacteria to acquire resistance determinants from other bacteria without sexual reproduction. The three mechanisms operate through distinct pathways. Conjugation requires direct physical contact between a donor and recipient cell via a pilus structure; the donor transfers a plasmid or chromosomal segment carrying resistance genes. Transformation involves uptake of naked deoxyribonucleic acid released from lysed bacteria by competent recipients. Transduction uses bacteriophage particles that accidentally package bacterial deoxyribonucleic acid and deliver it to new hosts upon infection. Conjugation is the most clinically consequential mechanism because it operates efficiently in clinical environments including within biofilms and the gastrointestinal tract, and because plasmids routinely carry multiple resistance determinants — extended-spectrum beta-lactamase genes, aminoglycoside-modifying enzyme genes, and fluoroquinolone resistance genes may coexist on a single plasmid, enabling an organism to acquire simultaneous resistance to three structurally unrelated drug classes through one conjugative event.

Correct Answer

C — vanA confers high-level resistance to both vancomycin and teicoplanin and is transferable by conjugation; vanB confers variable vancomycin resistance without teicoplanin resistance

Rationale

Both vanA and vanB gene clusters reprogram cell wall biosynthesis to produce peptidoglycan precursors terminating in D-alanyl-D-lactate rather than D-alanyl-D-alanine, reducing vancomycin binding affinity approximately 1,000-fold. The phenotypic differences are clinically meaningful. vanA is the more severe phenotype: it confers high-level resistance to vancomycin and also to teicoplanin (the glycopeptide widely used in Europe), and it is carried on transferable plasmids and transposons, enabling conjugative spread to other enterococcal strains and — in documented cases — to Staphylococcus aureus, creating vancomycin-resistant Staphylococcus aureus. vanB confers variable levels of vancomycin resistance but leaves teicoplanin active because the vanB operon is not induced by teicoplanin exposure. This means teicoplanin can be used to treat some vanB vancomycin-resistant Enterococcus infections. In practice, daptomycin and linezolid are the primary therapeutic options for vancomycin-resistant Enterococcus infections regardless of the van genotype.

Correct Answer

D — Single mutations in the primary target — deoxyribonucleic acid gyrase in gram-negatives, topoisomerase four in gram-positives — produce low- to moderate-level resistance; high-level resistance requires additional mutations in the secondary target; prolonged courses select for resistance through sequential single-step mutational accumulation

Rationale

Fluoroquinolones simultaneously trap both deoxyribonucleic acid gyrase and topoisomerase four as drug-enzyme-deoxyribonucleic acid ternary complexes. In gram-negative bacteria, deoxyribonucleic acid gyrase is the primary target; in gram-positives, topoisomerase four is primary. A single point mutation in the primary target enzyme — typically in the quinolone resistance-determining region of gyrA or parC — reduces drug binding affinity enough to produce low- to moderate-level resistance (elevated minimum inhibitory concentrations) while the drug may still exert some activity. High-level clinical resistance, which renders fluoroquinolones therapeutically unreliable, requires accumulation of mutations in both primary and secondary targets. The clinical importance: because resistance builds through sequential single steps rather than requiring two simultaneous mutations, prolonged fluoroquinolone courses create an extended selection window during which organisms with the first mutation are enriched, and secondary mutations can then occur in that pre-selected background. This stepwise selection is the basis for the recommendation to use the shortest effective fluoroquinolone course and to avoid prolonged courses when alternatives exist.

Correct Answer

B — Imipenem relies primarily on a specific outer membrane porin channel for periplasmic entry; loss of this porin, combined with efflux pump activity, reduces imipenem concentrations at the target below inhibitory levels while meropenem uses additional entry pathways and is a better efflux pump substrate, retaining some activity

Rationale

Pseudomonas aeruginosa outer membrane has limited baseline permeability and expresses constitutive multidrug efflux pumps. Imipenem enters the periplasm primarily through a dedicated outer membrane channel. When this porin is lost through mutation, imipenem influx falls dramatically, and residual drug that enters the periplasm is further reduced by efflux — the synergy between loss of the influx route and active efflux reduces imipenem concentrations below the minimum inhibitory concentration. Meropenem is less dependent on this same porin and has differential efflux pump interactions; it may retain activity against porin-deficient Pseudomonas aeruginosa when imipenem has failed. This phenomenon explains why susceptibility testing for both carbapenems is needed in Pseudomonas aeruginosa infections — imipenem and meropenem are not interchangeable in isolates with porin-based resistance. This resistance mechanism requires no carbapenemase gene, which is why it can coexist with carbapenem-susceptible phenotypes for the unaffected agent and why molecular carbapenemase screening may be negative in these isolates.

Correct Answer

D — The inoculum effect caused the initial susceptibility report to underestimate true resistance; at the high bacterial densities of bacteremia, extended-spectrum beta-lactamase activity overwhelms ceftriaxone, destroying the drug; the antibiotic must be changed to a carbapenem, which is not hydrolyzed by extended-spectrum beta-lactamases

Rationale

This is the classic extended-spectrum beta-lactamase inoculum effect failure. Standard susceptibility testing uses a controlled bacterial inoculum that may be insufficient to reveal extended-spectrum beta-lactamase activity against third-generation cephalosporins — particularly if the enzyme is expressed at relatively low levels. At the much higher bacterial concentrations present in bacteremia, the aggregate beta-lactamase enzyme activity produced by billions of organisms overwhelms the ceftriaxone, hydrolysis accelerates, and active drug concentrations fall below the minimum inhibitory concentration despite an apparently susceptible result. This outcome has been documented repeatedly in clinical series of extended-spectrum beta-lactamase-producing bacteremia treated with cephalosporins. The organism was extended-spectrum beta-lactamase-producing from the beginning — it did not acquire the gene during therapy. Treatment requires a carbapenem: extended-spectrum beta-lactamases belong to molecular class A and cannot hydrolyze the carbapenem ring. Adding a beta-lactamase inhibitor to ceftriaxone is unreliable because inhibitor concentrations in blood may be suboptimal to fully suppress the enzyme burden in high-inoculum infection.

Correct Answer

B — Enterobacter cloacae carries a chromosomal inducible AmpC gene; ceftriaxone selected for a pre-existing mutant subpopulation that constitutively overproduces AmpC, producing high-level cephalosporin resistance while the patient appeared to respond initially to killing of susceptible organisms

Rationale

Enterobacter cloacae is a member of the group of organisms with inducible chromosomal AmpC beta-lactamases. At baseline the AmpC gene is expressed at low levels, and the initial susceptibility test detects a ceftriaxone-susceptible population — hence the initial susceptible report and apparent early clinical response as ceftriaxone kills the susceptible majority. However, within the large population of organisms in a serious pneumonia, rare pre-existing mutants have regulatory mutations causing constitutive, high-level AmpC overproduction. Ceftriaxone is a potent AmpC inducer and simultaneously kills susceptible organisms while providing a selective advantage to the constitutive overproducer mutants. Over days, the constitutive mutants expand to dominate the population — producing the clinical picture of initial improvement followed by treatment failure with the same species, now resistant. This is AmpC derepression. The appropriate management is to avoid third-generation cephalosporins for serious infections caused by AmpC-harboring organisms and to use cefepime or a carbapenem, which are more stable to AmpC hydrolysis.

Correct Answer

A — Ceftaroline has sufficient affinity for penicillin-binding protein 2a to occupy and inhibit it at therapeutic concentrations, preventing the bypass transpeptidation that sustains cell wall synthesis in methicillin-resistant Staphylococcus aureus despite inhibition of all other penicillin-binding proteins

Rationale

The mechanism of methicillin-resistant Staphylococcus aureus resistance is a bypass strategy: penicillin-binding protein 2a, encoded by mecA, has such low affinity for beta-lactam antibiotics that all conventional agents fail to inhibit it at achievable drug concentrations, even while binding and inactivating all the normal penicillin-binding proteins. The organism survives because penicillin-binding protein 2a continues cross-linking peptidoglycan. Ceftaroline is the first approved beta-lactam with structural features — particularly its side chain configuration at the C-3 position — that allow it to bind the penicillin-binding protein 2a active site with sufficient affinity to inhibit transpeptidation at clinically achievable concentrations. With all penicillin-binding proteins including PBP2a now inhibited, cell wall synthesis fails and the organism is killed. This is a binding affinity solution to the bypass mechanism, not enzyme inhibition, prodrug conversion, or transcriptional suppression of the mecA gene.

Correct Answer

C — The vanA cluster reprograms cell wall biosynthesis to terminate peptidoglycan precursors with D-alanyl-D-lactate instead of D-alanyl-D-alanine; this substitution reduces vancomycin binding affinity approximately 1,000-fold, rendering the drug unable to block cell wall cross-linking

Rationale

The vanA resistance operon encodes a coordinated set of enzymes that rewire the terminal steps of peptidoglycan precursor biosynthesis. Normal precursors terminate in D-alanyl-D-alanine — the dipeptide to which vancomycin binds with high affinity through five hydrogen bonds. The vanA cluster encodes a depsipeptide ligase that substitutes D-lactic acid (an ester) for the terminal D-alanine, producing D-alanyl-D-lactate. This single ester-for-amide substitution eliminates one of the five hydrogen bonds that vancomycin forms with its target, reducing binding affinity approximately 1,000-fold — far below the concentration achievable clinically. Cell wall synthesis continues via the D-alanyl-D-lactate pathway while vancomycin cannot engage its target. The patient's lack of prior vancomycin exposure is consistent with this mechanism: vanA resistance is constitutively or inducibly encoded on transferable plasmids and transposons that spread through healthcare settings independently of selection pressure in any individual patient. The resistance was acquired through horizontal transfer from another vancomycin-resistant Enterococcus in the hospital environment, not selected by this patient's drug exposures.